Research background · Updated November 1, 2026
SLU-PP-332 Research: Publications, Study Types and Background
Short answer
SLU-PP-332. As of November 1, 2026, PubMed indexes 10 records matching SLU-PP-332, the earliest from 2023; 6 were published in 2021–2025 and 1 are reviews. ClinicalTrials.gov lists 0 registered studies matching the compound.
- PubMed records
- 10
- Earliest record
- 2023
- Published 2021–2025
- 6
- Reviews
- 1
- Animal-only studies
- 3
- Registered studies
- 0
Publications per year, 2006–2025
7 records in 2016–2025 against 0 in 2006–2015; the busiest year was 2023, with 3.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 0 |
| 2007 | 0 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 0 |
| 2011 | 0 |
| 2012 | 0 |
| 2013 | 0 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 0 |
| 2018 | 0 |
| 2019 | 0 |
| 2020 | 0 |
| 2021 | 0 |
| 2022 | 0 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
Study types
| All PubMed records | 10 |
|---|---|
| Reviews | 110% |
| Animal studies (no human subjects indexed) | 330% |
| Indexed as clinical trials | 00% |
| Registered on ClinicalTrials.gov | 0 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 2 of the most-cited and most recent SLU-PP-332 papers report, in their own authors’ terms. Each line links the paper it came from.
Energy expenditure and metabolism
In animal models, the estrogen-related receptor agonist SLU-PP-332 increased energy expenditure and fatty acid oxidation with less fat mass accumulation, and reduced obesity and improved insulin sensitivity in models of metabolic syndrome.
AnimalsBillon C 2024The Journal of pharmacology and experimental therapeuticsPMID 37739806
Heart failure models
In pressure-overload heart failure models, the ERR agonists SLU-PP-332 and SLU-PP-915 improved ejection fraction, reduced fibrosis and increased survival.
AnimalsXu W 2024CirculationPMID 37961903
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 10 of the 10 records. They describe what the literature is about, not what SLU-PP-332 does.
- Receptors, Estrogen6 papers
- Metabolic Syndrome1 papers
- Insulin Resistance1 papers
- Heart Failure1 papers
- Doping in Sports1 papers
- Kidney1 papers
- Inflammation1 papers
- Exercise Tolerance1 papers
Key papers
Earliest indexed record
Billon C (2023). ACS chemical biology.
PMID 36988910Most-cited paper · 58 citations
Xu W (2024). Circulation.
PMID 37961903Most-cited #2 · 42 citations
Wang XX (2023). The American journal of pathology.
PMID 37717940Most-cited #3 · 37 citations
Billon C (2023). ACS chemical biology.
PMID 36988910
Citation counts from NIH iCite, among the 10 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| CAS | 303760-60-3 |
|---|---|
| Molecular formula | C18H14N2O2 |
| Molecular weight | 290.3 g/mol |
| Synonyms | SLU-PP-332, CHEMBL4208749, MFCD00595076, ERR pan-Agonist 332, 5YW57G7ADL |
Identity data from PubChem, retrieved November 1, 2026, on the SLU-PP-332 page.
How these numbers were counted
- PubMed search, run November 1, 2026:
"SLU-PP-332"[tiab] OR "SLUPP-332"[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
"SLU-PP-332"re-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use SLU-PP-332 outside a laboratory.
Wholesale supply
SLU-PP-332, sourced to order for research.
Not held in the listed catalog. Tell us the vial size and the number of vials and we come back with availability, documentation and pricing in writing.
SLU-PP-332 research questions
How much research has been published on SLU-PP-332?
PubMed indexes 10 records matching SLU-PP-332 (searched November 1, 2026), including 1 reviews and 0 records indexed as clinical trials. 6 were published in the five years 2021–2025.
When was SLU-PP-332 first described in the literature?
The earliest PubMed record matching SLU-PP-332 is from 2023 (Billon C, ACS chemical biology, PMID 36988910).
What topics does the SLU-PP-332 literature cover?
The subject headings PubMed indexers most often marked as a main topic of SLU-PP-332 papers are Receptors, Estrogen, Metabolic Syndrome, Insulin Resistance, Heart Failure. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
Is SLU-PP-332 sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy SLU-PP-332 wholesale for research?
We source SLU-PP-332 to order rather than stock it. Tell us the vial size and number of vials on WhatsApp or by email and the quote confirms availability, documentation and pricing.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.